|
Invited Speakers:
|
|
CONFIRMED SPEAKERS
•Alan Wilson, Vice President, Drug Metabolism & Pharmacokinetics, Lexicon Genetics
•Dr. Chetan Lathia, Director, Global Clinical Pharmacology, Bayer
•David Slavin, Executive Director, World Wide Development Business Innovations Unit, Pfizer
•Professor Gordon Duff, Chairman, Commission on Human Medicines, Florey Professor of Molecular Medicine, University of Sheffield School of Medicine*
•Calvert Louden, Head, Department of Safety Assessment, AstraZeneca
•Hermann-Josef Huss, Head, Data Acquisition & Management Europe & Overseas, Bayer HealthcareINVITED SPEAKERS INCLUDE
•Dr. Steven W. Ryder, Senior Vice President & Director, Worldwide Clinical Development, Pfizer
•Dr. Klaus Lindpaintner, Vice President, Roche Genomics F. Hoffmann - La Roche
•Dr. Mark Boguski, Vice President & Global Head of Genome & Proteome Sciences, Novartis
•Dr. Isaac Kobrin, Senior Vice President, Head of Clinical Development, Actelion
•Dr. Thomas Senderovitz, Vice President, Experimental Medicine Global Clinical R&D, Ferring Pharmaceuticals
•Dr. Steven Gutman, Director, Office of In Vitro Diagnostic Device Evaluation and Patient Safety (OIVD), Center for Devices and Radiological Health (CDRH), FDA
•Dr. Carl Alden, Vice President, Molecular Investigative, Toxicology, Millennium Pharmaceuticals
•Dr. Eric Blomme, Project Leader, Cell & Molecular Toxicology, Abbott
•Dr. Johannes Lampe, Neurologist, Director, Global Medical Development Specialized Therapeutics, Schering AG
•Dr. Mauro D'Antonio, Section Head, Biomarker Group, Merck-Serono
•Dr. Orest Hurko, Assistant Vice President, Translational Research, Wyeth
•Dr. Harsukh Parmar, Director, Global Discovery Medicine, Respiratory & Inflammation Therapy, AstraZeneca
•Dr. Andrew J. Dorner, Senior Director, Molecular Profiling & Biomarker Discovery, Wyeth Research
•Dr. Alain van Gool, Section Head Genomics & Proteomics, Chair Biomarker Platform, Organon
|
|